Gabriela Ciszek

Ms. Gabriela Ciszek

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 July 2025 in Sztuka Leczenia
Verified
Journal Article
Open access
PDF file
KDKarolina Duczmal
Karolina Duczmal
ZSZuzanna Słowińska
Zuzanna Słowińska
GCGabriela Ciszek
Gabriela Ciszek
ZKZofia Kowal
Zofia Kowal
KKKornelia Kręciszewska
Kornelia Kręciszewska
KPKatarzyna Pekacka-Falkowska
Katarzyna Pekacka-Falkowska
Artykuł przedstawia przegląd historycznych metod leczenia raka piersi, od starożytności po czasy współczesne. Śledzi rozwój teorii medycznych i podejść terapeutycznych, wskazując na najważniejsze postacie oraz kamienie milowe. Omawia praktyki starożytnego świata, wyodrębniając postępowanie chirurgiczne, rozwój radio- i chemioterapii, a także początki terapii celowanych. Pokazuje, jak minione innowacje i odkrycia kształtują współczesną medycynę i wpływają na jej dalszy rozwój. Część pierwsza artykułu przedstawia najstarsze sposoby podejścia do terapii raka piersi, charakterystyczne dla świata starożytnego. Skupia się na materiałach historycznych wytworzonych przez cywilizacje antyczne, m.in. Egipt, Grecję, Rzym, Indie i Chiny, aby ukazać, jak ich przedstawiciele rozumieli i leczyli nowotwory sutka.

8 January 2026 in Sztuka Leczenia
Verified
Journal Article
Open access
PDF file
KKKornelia Kręciszewska
Kornelia Kręciszewska
KŻKarolina Magdalena Żyto
Karolina Magdalena Żyto
GCGabriela Ciszek
Gabriela Ciszek
KDKarolina Duczmal
Karolina Duczmal
ZKZofia Kowal
Zofia Kowal
ZSZuzanna Słowińska
Zuzanna Słowińska
Niniejszy artykuł jest drugim z kolei segmentem trzyczęściowego cyklu artykułów na temat historii leczenia raka sutka od czasów starożytnych po współczesność. Stanowi bezpośrednią kontynuację części pierwszej wydanej w poprzednim numerze czasopisma, opisującej to zagadnienie w starożytności. W poniższej części zaprezentowano metody leczenia oraz koncepcje patogenezy wspomnianego schorzenia prezentowane w źródłach historycznych średniowiecznej Europy, średniowiecznego świata islamskiego, Bizancjum oraz w okresie renesansu, baroku i oświecenia.

30 June 2026 in Sztuka Leczenia
Verified
Journal Article
Open access
GCGabriela Ciszek
Gabriela Ciszek
ZKZofia Kowal
Zofia Kowal
KDKarolina Duczmal
Karolina Duczmal
KKKornelia KręCiszewska
Kornelia KręCiszewska
ZSZuzanna Słowińska
Zuzanna Słowińska
KPKatarzyna Pekacka-Falkowska
Katarzyna Pekacka-Falkowska
W trzeciej części cyklu poświęconej terapii raka piersi przedstawiono podejścia, które rodziły się w wieku XIX i XX. Prześledzono zarówno rozwój nowych teorii medycznych, jak i technik operacyjnych oraz innych form leczenia. Tekst stanowi trzecią i zarazem ostatnią część cyklu poświęconego historii leczenia raka piersi. W poprzednich dwóch przybliżono temat leczenia nowotworu sutka w okresie starożytności oraz średniowiecza i renesansu.

31 December 2025 in Archiv Euromedica
Verified
Journal Article
Closed access
OHOlaf Helbig
Olaf Helbig
GCGabriela Ciszek
Gabriela Ciszek
BBBartłomiej Bobrowski
Bartłomiej Bobrowski
HDHonorata Derlatka
Honorata Derlatka
JDJan Drugacz
Jan Drugacz
ŁSŁukasz Skowron
Łukasz Skowron
Background: The rapidly increasing global prevalence of e-cigarette use, particularly among adolescents and young adults, has raised significant concern regarding their respiratory safety. E-cigarettes generate an aerosol by heating a liquid mixture containing nicotine, propylene glycol, vegetable glycerin, flavorings, and various toxic and potentially carcinogenic compounds such as aldehydes, acrolein, and heavy metals. The respiratory system, being the primary route of exposure, is especially vulnerable to both acute and chronic toxic effects. Aims: This review aims to synthesize and critically evaluate current evidence on the respiratory consequences of e-cigarette use, with a focus on acute and chronic pulmonary effects, underlying cellular and molecular mechanisms of injury, and implications for public health and clinical practice. Methods: A narrative review was conducted following a structured literature search in PubMed, Scopus, Web of Science, and Embase for studies published between 2018 and 2025. The search included the terms “e-cigarette”, “vaping”, “respiratory system”, “lung injury”, “EVALI”, “oxidative stress”, “nicotine”, and “pulmonary disease”. The initial search identified 246 records; after screening and eligibility assessment, 74 studies were included. Priority was given to systematic reviews, meta-analyses, and large-scale observational or experimental studies. Data were synthesized narratively with emphasis on methodological rigor, quality of evidence, and consistency of findings. Results: E-cigarette use was shown to cause both acute and chronic respiratory injury. Acute effects include airway inflammation, oxidative stress, and epithelial barrier disruption, while chronic exposure is linked to persistent inflammation, bronchial remodeling, and increased risk of asthma and chronic obstructive pulmonary disease. The 2019 EVALI outbreak exemplified the acute toxicity potential, particularly from illicit THC-containing products adulterated with vitamin E acetate. Experimental studies confirm mitochondrial dysfunction and DNA damage, indicating genotoxic and pro-carcinogenic mechanisms already in progress. Epidemiological data consistently show higher prevalence of respiratory symptoms and reduced lung function among e-cigarette users compared with non-users, including those who have never smoked combustible cigarettes. However, interpretation must remain cautious due to methodological heterogeneity, self-reported exposure data, and limited long-term follow-up. Conclusions: Current evidence demonstrates that e-cigarettes are not harmless and should be recognized as independent respiratory risk factors. Although they differ from conventional tobacco products, they induce distinct pathophysiological effects mediated by oxidative stress, inflammation, and epithelial dysfunction. The long-term carcinogenic potential remains uncertain because of limited longitudinal data, yet biomarker evidence indicates possible genotoxicity. Persistent research gaps include the long-term impact of novel flavoring agents, standardized exposure assessment, and dose–response relationships. Continuous high-quality longitudinal research and stronger regulatory measures are essential to mitigate health risks and protect vulnerable populations.

Verified
Journal Article
Open access
PDF file
DSDawid Szpecht
Dawid Szpecht
KŻKarolina Magdalena Żyto
Karolina Magdalena Żyto
GCGabriela Ciszek
Gabriela Ciszek
KDKarolina Duczmal
Karolina Duczmal
ZKZofia Kowal
Zofia Kowal
ASAgnieszka Seremak-Mrozikiewicz
Agnieszka Seremak-Mrozikiewicz
The objective of the present study is to examine the association between the presence of various forms of matrix metalloproteinase genes (MMP-1, MMP-9, TIMP-1 and TIMP-2) and their tissue inhibitors, and the incidence of intraventricular haemorrhage (IVH) in premature neonates. The data for this study were obtained from samples of peripheral venous blood, which were collected and stored post-delivery. The techniques employed for the purpose of genotyping were polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP). The population that was examined comprised 100 patients with a gestational age (GA) ranging from 22 to 33 weeks and birth weight (BW) ranging from 432 to 2100 g. In the cohort of enrolled patients, 48 cases of IVH were observed. As indicated by the findings of this study, the majority of observed correlations between MMP-1, MMP-9, TIMP-1, and TIMP-2 variants and IVH did not demonstrate statistical significance, with the exception of the T allele of TIMP1 rs4898. Nevertheless, the findings of this study indicated a potential impact of these variants on the incidence of IVH. The present study suggests that further research is required to elucidate the role of MMP/TIMP polymorphisms in the aforementioned disease.

30 April 2026 in Archiv Euromedica
Verified
Journal Article
Closed access
FCFilip Chodań
Filip Chodań
OHOlaf Helbig
Olaf Helbig
GCGabriela Ciszek
Gabriela Ciszek
Background Eosinophilic esophagitis is a chronic immune mediated disease characterized by eosinophilic infiltration of the esophageal mucosa and symptoms of esophageal dysfunction. Despite the use of proton pump inhibitors, topical corticosteroids, and dietary interventions, a substantial proportion of patients does not achieve adequate clinical response. Biologic therapy has emerged as a targeted treatment option, however available evidence remains heterogeneous and requires critical synthesis. Aims To provide a comprehensive overview of current evidence on biologic therapy in eosinophilic esophagitis and to evaluate its clinical relevance based on histological, endoscopic, and symptomatic outcomes. Methods This study was designed as a narrative review. Literature was identified using PubMed and complementary open access sources, including PubMed Central, Google Scholar, DOAJ, ClinicalTrials.gov, and other open repositories. The search covered publications up to March 16, 2026, with prioritization of studies from the last five years. Selection of sources was based on relevance to the objectives of the review rather than systematic screening. A total of 54 publications were included. Results Biologic therapies consistently reduce eosinophilic inflammation, however their clinical efficacy varies depending on the targeted pathway. Dupilumab demonstrates the most consistent improvement across histological, endoscopic, and clinical outcomes. In contrast, therapies targeting IL 5, IL 5R, and IL 13 are associated with reduction in eosinophil counts without consistent symptom improvement. Emerging therapies targeting TSLP, Siglec 8, IL 15, and KIT demonstrate biological activity, but their clinical significance remains uncertain. Conclusions Biologic therapy in eosinophilic esophagitis shows heterogeneous effectiveness and depends on the targeted mechanism. Dupilumab currently represents the most clinically validated option. Other biologic agents demonstrate partial or preliminary effects. The findings should be interpreted with caution due to the narrative design of the review and non-systematic study selection.